Welcome to our dedicated page for Praxis Precision Medicines news (Ticker: PRAX), a resource for investors and traders seeking the latest updates and insights on Praxis Precision Medicines stock.
Praxis Precision Medicines, Inc. (NASDAQ: PRAX) is a clinical-stage biopharmaceutical company focused on central nervous system (CNS) disorders characterized by neuronal excitation–inhibition imbalance. The PRAX news page on Stock Titan aggregates company announcements, clinical updates, regulatory milestones and capital markets activity related to its precision neuroscience pipeline.
Investors and followers of Praxis can use this page to track developments across the company’s diversified CNS portfolio. News items include progress updates on late-stage product candidates such as ulixacaltamide for essential tremor, vormatrigine for focal onset seizures and generalized epilepsy, relutrigine for developmental and epileptic encephalopathies (DEEs), and elsunersen for early-onset SCN2A-DEE. Praxis frequently reports on Phase 2 and Phase 3 study readouts, FDA interactions such as pre-NDA meetings and Breakthrough Therapy Designations, and changes to registrational trial designs.
The feed also covers corporate and financial disclosures, including underwritten public offerings, at-the-market equity programs, and governance or leadership changes. Form 8-K filings referenced in press releases provide additional detail on clinical data, regulatory feedback and financing terms. Because Praxis emphasizes precision neuroscience and genetic epilepsies, its news often highlights mechanistic data, biomarker findings and functional outcomes in epilepsy and movement disorder studies.
By reviewing this PRAX news stream, readers can follow key catalysts such as NDA preparation, pivotal trial milestones, regulatory designations and capital raises that may influence the company’s trajectory as it advances its CNS portfolio. Bookmark this page to access an organized view of Praxis Precision Medicines’ latest public communications and disclosures.
Praxis Precision Medicines (NASDAQ: PRAX) provided a corporate update and reported financial results for Q2 2022. The company has $165.4 million in cash as of June 30, supporting operations into Q1 2024. Key clinical highlights include encouraging topline results from the Phase 2a study of PRAX-944 for essential tremor and the completion of the Phase 1 study for PRAX-562, confirming its potential therapeutic window. However, the PRAX-114 Phase 2 study for major depressive disorder was discontinued due to failure to meet statistical significance.
Praxis Precision Medicines (NASDAQ: PRAX) announced its participation in the Wedbush PacGrow Healthcare Virtual Conference on August 10, 2022, at 12:35 p.m. ET. The panel, titled “Got My Mind Set On You – Advancing Novel Epilepsy Targets,” will focus on therapies addressing central nervous system (CNS) disorders characterized by neuronal excitation-inhibition imbalance. Interested parties can access the live webcast via the company’s website, where a replay will be available for 30 days post-event. Praxis is committed to developing innovative solutions for various CNS disorders.
Praxis Precision Medicines announced that the Phase 2/3 Aria Study for PRAX-114 in treating major depressive disorder did not achieve statistical significance on its primary endpoint. Despite well-tolerated results, the study's failure is disappointing for the company. In response, Praxis will refocus resources on its Movement Disorders and Epilepsy franchises, extending its cash runway into 2024. The company plans to prioritize Phase 2b results for PRAX-944 and proof-of-concept for PRAX-562.
Praxis Precision Medicines (NASDAQ: PRAX) has appointed Jill DeSimone to its board of directors, enhancing its leadership with her extensive experience in oncology and pharmaceuticals. DeSimone previously served as President of U.S. Oncology at Merck & Co. and has a notable background at other leading firms like Teva and Bristol Myers Squibb. Her expertise in product launches and patient care aligns with Praxis's mission to develop therapies for CNS disorders. The company is optimistic about leveraging her insights during a pivotal time for its growth and product development.
Praxis Precision Medicines (NASDAQ: PRAX) has announced its participation in two upcoming investor conferences. The first is the Citi Biotech Virtual Co-Panel Day on May 18, 2022, featuring panels on 'Mood Disorders/Mental Health' at 11:00 a.m. ET and 'Movement Disorders/Epilepsy' at 3:30 p.m. ET. The second is the H.C. Wainwright Global Investment Conference, where a company presentation will be available on May 24, 2022, at 7:00 a.m. ET. Webcasts of these events can be accessed on their website, with replays available for 90 days.
Praxis Precision Medicines (NASDAQ: PRAX) provided a corporate update on May 9, 2022, highlighting positive results from its Phase 2a study of PRAX-944 for essential tremor. The drug showed a 42% mean improvement in the Modified Activities of Daily Living score. The PRAX-114 Aria Study for Major Depressive Disorder is also complete, with topline results expected in June 2022. The company reported a cash balance of $222.5 million as of March 31, 2022, a decrease from $275.9 million, and a net loss of $68.7 million in Q1 2022.
PRAX-944 has shown promising results in the Phase 2a study for treating essential tremor (ET). A mean improvement of 42% in the Modified Activities of Daily Living score was observed by Day 42, with a significant distinction during the randomized withdrawal phase. The treatment was well-tolerated with no new safety findings. Following these results, Praxis intends to update the primary endpoint for the Phase 2b Essential1 study to focus on efficacy, indicating progress towards a potential treatment for ET patients.
Praxis Precision Medicines (NASDAQ: PRAX) announced participation in a fireside chat at the BofA Securities 2022 Healthcare Conference on May 11, 2022, at 5:00 p.m. ET. The event will be accessible via live webcast on the company's website, with a replay available for 90 days post-event. Praxis focuses on developing therapies for central nervous system disorders linked to neuronal excitation-inhibition imbalance, leveraging genetic insights. The company has multiple clinical-stage product candidates addressing psychiatric and movement disorders, and epilepsy.
Praxis Precision Medicines (NASDAQ: PRAX) announced a corporate update and financial results for Q1 2022 set for May 9, 2022, post-market close. The management will share a video highlighting business and pipeline progress, followed by a live Q&A at 4:30 p.m. ET. Praxis is focused on developing therapies for CNS disorders linked to neuronal imbalances and boasts a broad portfolio, including multiple clinical-stage product candidates addressing various neurological and psychiatric disorders. For more, visit Praxis Medicines.
Praxis Precision Medicines hosted its 2022 Epilepsy Day in New York City, showcasing its advancements in treating CNS disorders. CEO Marcio Souza highlighted their innovative approaches and significant progress across three major epilepsy programs: PRAX-222, PRAX-562, and PRAX-628, all expected to reach clinical stages by the end of 2022. The company aims to address unmet needs in epilepsy management with targeted therapies. This event emphasized Praxis' multi-billion-dollar market opportunity in the epilepsy sector, reflecting its commitment to rapid drug development driven by genetic insights.